SICI-GISE Position paper : Use of Absorb BVS in clinical practice
Drug-eluting stents (DES) are the current gold standard for percutaneous treatment of coronary artery disease. However, DES are associated with a non-negligible risk of long-term adverse events related to persistence of foreign material in the coronary artery wall. In addition, DES implantation causes permanent caging of the native vessel, thus impairing normal vasomotricity and the possibility of using non-invasive coronary imaging or preforming subsequent bypass surgery. On the contrary, coronary bioresorbable stents (BRS) may provide temporary mechanical support to coronary wall without compromising the subsequent recovery of normal vascular physiology, and have the potential to prevent late adverse events related to permanent elements. Several types of BRS have been introduced into clinical practice in Europe or are being tested. However, most of available clinical data relate to a single BRS, the Absorb bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA). Despite encouraging clinical results, no societal guidelines are available on the use of BRS in clinical practice.A panel of Italian expert cardiologists assembled under the auspices of the Italian Society of Interventional Cardiology (SICI-GISE) for comprehensive discussion and consensus development, with the aim to provide recommendations on the use of bioresorbable stents in terms of clinical indications, procedural aspects, post-percutaneous coronary angioplasty pharmacologic treatment and follow-up. Based on current evidence and BRS availability in Italian cath-labs, the panel decided unanimously to provide specific recommendations for the Absorb BVS device. These recommendations do not necessarily extend to other BRS, unless specified, although significant overlap may exist with Absorb BVS, particularly in terms of clinical rationale.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Giornale italiano di cardiologia (2006) - 17(2016), 10 Suppl 1 vom: 12. Okt., Seite 28S-44 |
Sprache: |
Italienisch |
---|
Weiterer Titel: |
Documento di posizione SICI-GISE: Utilizzo di Absorb BVS nella pratica clinica |
---|
Beteiligte Personen: |
Tarantini, Giuseppe [VerfasserIn] |
---|
Links: |
---|
Themen: |
Cardiovascular Agents |
---|
Anmerkungen: |
Date Completed 19.06.2017 Date Revised 19.06.2017 published: Print Citation Status MEDLINE |
---|
doi: |
10.1714/2372.25480 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM265211190 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM265211190 | ||
003 | DE-627 | ||
005 | 20231224211804.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2016 xx |||||o 00| ||ita c | ||
024 | 7 | |a 10.1714/2372.25480 |2 doi | |
028 | 5 | 2 | |a pubmed24n0884.xml |
035 | |a (DE-627)NLM265211190 | ||
035 | |a (NLM)27729667 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a ita | ||
100 | 1 | |a Tarantini, Giuseppe |e verfasserin |4 aut | |
245 | 1 | 0 | |a SICI-GISE Position paper |b Use of Absorb BVS in clinical practice |
246 | 3 | 3 | |a Documento di posizione SICI-GISE: Utilizzo di Absorb BVS nella pratica clinica |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.06.2017 | ||
500 | |a Date Revised 19.06.2017 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Drug-eluting stents (DES) are the current gold standard for percutaneous treatment of coronary artery disease. However, DES are associated with a non-negligible risk of long-term adverse events related to persistence of foreign material in the coronary artery wall. In addition, DES implantation causes permanent caging of the native vessel, thus impairing normal vasomotricity and the possibility of using non-invasive coronary imaging or preforming subsequent bypass surgery. On the contrary, coronary bioresorbable stents (BRS) may provide temporary mechanical support to coronary wall without compromising the subsequent recovery of normal vascular physiology, and have the potential to prevent late adverse events related to permanent elements. Several types of BRS have been introduced into clinical practice in Europe or are being tested. However, most of available clinical data relate to a single BRS, the Absorb bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA). Despite encouraging clinical results, no societal guidelines are available on the use of BRS in clinical practice.A panel of Italian expert cardiologists assembled under the auspices of the Italian Society of Interventional Cardiology (SICI-GISE) for comprehensive discussion and consensus development, with the aim to provide recommendations on the use of bioresorbable stents in terms of clinical indications, procedural aspects, post-percutaneous coronary angioplasty pharmacologic treatment and follow-up. Based on current evidence and BRS availability in Italian cath-labs, the panel decided unanimously to provide specific recommendations for the Absorb BVS device. These recommendations do not necessarily extend to other BRS, unless specified, although significant overlap may exist with Absorb BVS, particularly in terms of clinical rationale | ||
650 | 4 | |a Consensus Development Conference | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Practice Guideline | |
650 | 7 | |a Cardiovascular Agents |2 NLM | |
700 | 1 | |a Saia, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Capranzano, Piera |e verfasserin |4 aut | |
700 | 1 | |a Cortese, Bernardo |e verfasserin |4 aut | |
700 | 1 | |a Mojoli, Marco |e verfasserin |4 aut | |
700 | 1 | |a Boccuzzi, Giacomo |e verfasserin |4 aut | |
700 | 1 | |a Cuculo, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Geraci, Salvatore |e verfasserin |4 aut | |
700 | 1 | |a Mattesini, Alessio |e verfasserin |4 aut | |
700 | 1 | |a Oreglia, Jacopo |e verfasserin |4 aut | |
700 | 1 | |a Summaria, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Testa, Luca |e verfasserin |4 aut | |
700 | 1 | |a Berti, Sergio |e verfasserin |4 aut | |
700 | 1 | |a Esposito, Giovanni |e verfasserin |4 aut | |
700 | 1 | |a La Manna, Alessio |e verfasserin |4 aut | |
700 | 1 | |a Limbruno, Ugo |e verfasserin |4 aut | |
700 | 1 | |a Marchese, Alfredo |e verfasserin |4 aut | |
700 | 1 | |a Mauro, Ciro |e verfasserin |4 aut | |
700 | 1 | |a Tarantino, Fabio |e verfasserin |4 aut | |
700 | 1 | |a Salvi, Alessandro |e verfasserin |4 aut | |
700 | 1 | |a Santoro, Gennaro |e verfasserin |4 aut | |
700 | 1 | |a Varbella, Ferdinando |e verfasserin |4 aut | |
700 | 1 | |a Violini, Roberto |e verfasserin |4 aut | |
700 | 1 | |a Musumeci, Giuseppe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Giornale italiano di cardiologia (2006) |d 2006 |g 17(2016), 10 Suppl 1 vom: 12. Okt., Seite 28S-44 |w (DE-627)NLM16119561X |x 1972-6481 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2016 |g number:10 Suppl 1 |g day:12 |g month:10 |g pages:28S-44 |
856 | 4 | 0 | |u http://dx.doi.org/10.1714/2372.25480 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2016 |e 10 Suppl 1 |b 12 |c 10 |h 28S-44 |